Achieve Life Sciences Announces Publication Of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial In Journal Of The American Medical Association
Portfolio Pulse from Benzinga Newsdesk
Achieve Life Sciences has announced the publication of its Phase 3 ORCA-2 Smoking Cessation Trial in the Journal of the American Medical Association. The trial demonstrated the efficacy and tolerability of cytisinicline, a potential pharmacotherapy for smoking cessation. This could be the first such therapy approved in nearly two decades.
July 11, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The publication of Achieve Life Sciences' Phase 3 ORCA-2 Smoking Cessation Trial results could potentially boost the company's stock as it shows the efficacy of cytisinicline, a potential smoking cessation therapy.
The publication of positive trial results in a reputable journal like JAMA is a significant milestone for Achieve Life Sciences. It not only validates the efficacy of cytisinicline but also increases the likelihood of it being approved as a smoking cessation therapy. This could potentially lead to increased revenues for the company, thereby boosting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
While SCHV is mentioned in the article, it does not appear to be directly impacted by the news of Achieve Life Sciences' Phase 3 ORCA-2 Smoking Cessation Trial results.
SCHV is mentioned in the article, but there is no clear link between the ETF and the news about Achieve Life Sciences' Phase 3 ORCA-2 Smoking Cessation Trial results. Therefore, it is unlikely that this news will have a significant impact on SCHV's price.
CONFIDENCE 90
IMPORTANCE 10
RELEVANCE 10